2,089
Participants
Start Date
May 2, 2016
Primary Completion Date
August 14, 2018
Study Completion Date
August 14, 2018
Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG
Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Extavia (interferon beta-1b), Novartis Pharma AG
Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Rebif (interferon beta-1a), Merck Serono Europe Ltd
Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Plegridy (peginterferon beta-1a), Biogen Idec Ltd
Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Avonex (interferon beta-1a), Biogen Idec Ltd
Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)
Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
No MSDMDs therapy (control)
Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Many locations, Multiple Locations
Lead Sponsor
Collaborators (3)
EPID Research
UNKNOWN
Biogen
INDUSTRY
Merck Serono Europe Ltd
UNKNOWN
Novartis Pharmaceuticals
INDUSTRY
Bayer
INDUSTRY